Detail View

Reactive Oxygen Species-Responsive Miktoarm Amphiphile for Triggered Intracellular Release of Anti-Cancer Therapeutics
Citations

WEB OF SCIENCE

Citations

SCOPUS

Metadata Downloads

Title
Reactive Oxygen Species-Responsive Miktoarm Amphiphile for Triggered Intracellular Release of Anti-Cancer Therapeutics
DGIST Authors
Kim, Hyun-ChulKim, EunjooLee, Se GeunLee, Sung JunJeong, Sang WonLee, Young JaeKwon, Mi KyungChoi, Seong-KyoonHwang, Jun SeongChoi, Eun-Sook
Issued Date
2021-12
Citation
Kim, Hyun-Chul. (2021-12). Reactive Oxygen Species-Responsive Miktoarm Amphiphile for Triggered Intracellular Release of Anti-Cancer Therapeutics. doi: 10.3390/polym13244418
Type
Article
Author Keywords
drug delivery systemmiktoarm amphiphileROS-responsivetocopheryl derivatetumor therapy
Keywords
BLOCK-COPOLYMERSDRUG-DELIVERYVITAMIN-EMICELLESCANCERPOLYMERNANOCARRIERSEFFICIENTBIODISTRIBUTIONNANOPARTICLES
ISSN
2073-4360
Abstract
Reactive oxygen species (ROS)-responsive nanocarriers have received considerable research attention as putative cancer treatments because their tumor cell targets have high ROS levels. Here, we synthesized a miktoarm amphiphile of dithioketal-linked ditocopheryl polyethylene glycol (DTTP) by introducing ROS-cleavable thioketal groups as linkers between the hydrophilic and hydrophobic moieties. We used the product as a carrier for the controlled release of doxorubicin (DOX). DTTP has a critical micelle concentration (CMC) as low as 1.55 µg/mL (4.18 × 10−4 mM), encapsulation efficiency as high as 43.6 ± 0.23% and 14.6 nm particle size. The DTTP micelles were very responsive to ROS and released their DOX loads in a controlled manner. The tocopheryl derivates linked to DTTP generated ROS and added to the intracellular ROS in MCF-7 cancer cells but not in HEK-293 normal cells. In vitro cytotoxicity assays demonstrated that DOX-encapsulated DTTP micelles displayed strong antitumor activity but only slightly increased apoptosis in normal cells. This ROS-triggered, self-accelerating drug release device has high therapeutic efficacy and could be a practical new strategy for the clinical application of ROS-responsive drug delivery systems. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
URI
http://hdl.handle.net/20.500.11750/15983
DOI
10.3390/polym13244418
Publisher
MDPI AG
Show Full Item Record

File Downloads

공유

qrcode
공유하기

Related Researcher

김현철
Kim, Hyun-Chul김현철

Division of Biomedical Technology

read more

Total Views & Downloads